替尔泊肽 Tirzepatide

Tirzepatide is the first approved drug to simultaneously activate two separate metabolic receptors — GIP and GLP-1 — and the clinical trial data behind it is some of the most striking in the history of obesity medicine. In the SURMOUNT-1 trial, patients on the highest dose lost an average of 22.5% of their body weight over 72 weeks.^[1] For context, that's a 250-pound person losing roughly 56 pounds. That's a big number.

It's sold under two brand names by Eli Lilly: Mounjaro for type 2 diabetes (FDA-approved May 2022) and Zepbound for chronic weight management (FDA-approved November 2023). The molecule is identical — a 39-amino acid synthetic peptide administered as a once-weekly subcutaneous injection. The brand name just depends on what your doctor is prescribing it for.

If you've been following the GLP-1 space, tirzepatide sits one step above semaglutide in terms of both mechanism complexity and observed efficacy. Whether that difference matters for you specifically depends on your metabolic profile, your tolerance for GI side effects, and frankly, your insurance situation.

Key Takeaways

• Tirzepatide is FDA-approved under two brand names: Mounjaro (type 2 diabetes) and Zepbound (obesity/weight management).

It targets both GIP and GLP-1 receptors — a dual mechanism that produces greater average weight loss than GLP-1-only drugs like semaglutide in available trial data.

The SURMOUNT-1 trial showed mean weight loss of 20.9% at 10 mg and 22.5% at 15 mg over 72 weeks — the highest figures for any approved weight-loss drug.

Most side effects are gastrointestinal and concentrated during the dose-escalation phase; they typically improve once you reach a stable dose.

Compounded tirzepatide has been available through licensed 503B outsourcing facilities, though FDA has moved to restrict compounding as supply normalizes.

Class	Dual GIP/GLP-1 Receptor Agonist
Amino Acids	39
Mechanism	Simultaneous GIP receptor and GLP-1 receptor agonism
FDA Status	Approved — Mounjaro (T2D, 2022), Zepbound (obesity, 2023)
Administration	Subcutaneous injection, once weekly
Typical Dose	2.5 mg → 5 mg → 10 mg → 15 mg (escalated over ~20 weeks)
Half-life	~5 days
Primary Uses	Type 2 Diabetes, Chronic Weight Management
Manufacturer	Eli Lilly

The standard escalation protocol starts at 2.5 mg once weekly for four weeks, then increases by 2.5 mg every four weeks until reaching the target maintenance dose. That puts most patients at their assigned maintenance dose around week 20. The slow ramp-up isn't arbitrary — it's specifically designed to let your GI system adjust and minimize nausea during the early weeks.

22.5% mean weight loss at 15 mg over 72 weeks — SURMOUNT-1 trial

The SURMOUNT-1 trial tested three maintenance doses — 5 mg, 10 mg, and 15 mg — in adults with obesity but without type 2 diabetes.^[1] Here's what the dose-response curve looked like:

SURMOUNT-1 Dose-Response: Weight Loss at 72 Weeks

Outcome	5 mg	10 mg	15 mg
Mean weight loss (%)	~15.0%	~19.5%	~20.9%
≥20% weight loss (participants)	—	—	~57%
Placebo-adjusted weight loss	~12%	~17%	~18%
Maintenance dose reached at	~Week 8	~Week 16	~Week 20

[VERIFY: Precise per-arm percentages from SURMOUNT-1 — figures above are approximate from published abstract data; confirm exact values from full trial publication PMID 35658024 before publishing]

The dose-response relationship is real but not linear. Going from 10 mg to 15 mg produces a meaningful additional effect for many patients, but some people plateau at 10 mg and don't see much additional benefit from escalating further. That's a conversation to have with your prescriber based on your response at each step.

For type 2 diabetes, the SURPASS trial program tested similar dose ranges and found that tirzepatide outperformed semaglutide 1 mg on both HbA1c reduction (a 90-day average of blood glucose) and weight loss at all three doses.^[2]

SURMOUNT-4: What happens if you stop?

The SURMOUNT-4 trial answered a question a lot of patients ask: what happens when you stop taking it? Participants who completed an initial 36-week open-label tirzepatide period were then randomized to continue tirzepatide or switch to placebo for another 52 weeks. Those who continued lost an additional ~5.5% of body weight; those who switched to placebo regained roughly two-thirds of what they'd lost.^[3] This is consistent with what we see across the GLP-1 class — the drug is managing a chronic condition, not curing it.

The honest answer is: the GIP receptor. Every other approved weight-loss drug in this class — semaglutide, liraglutide — works exclusively through GLP-1 receptors. Tirzepatide adds GIP (glucose-dependent insulinotropic polypeptide) receptor activation on top of that, and the combination produces meaningfully better outcomes than GLP-1 alone.

What's interesting from a pharmacology standpoint is that tirzepatide isn't just a GLP-1 agonist with a GIP add-on. The molecule was engineered as a single peptide that binds both receptors with different affinities — it has higher affinity for GIP receptors than for GLP-1 receptors, which is the opposite of what you might expect given that GLP-1 drugs came first and GIP was historically considered less important for weight regulation.^[2]

The SURPASS-2 trial put this to a direct test, comparing tirzepatide head-to-head against semaglutide 1 mg in over 1,800 patients with type 2 diabetes. At 40 weeks, tirzepatide at 15 mg produced a 2.46 percentage point reduction in HbA1c — roughly a 2.5-point drop in that 90-day blood sugar average — compared to 1.86 points for semaglutide.^[2] Weight loss followed the same pattern: 12.4 kg for tirzepatide 15 mg versus 6.2 kg for semaglutide 1 mg. That's not a marginal difference.

“ Tirzepatide was engineered to hit two metabolic receptors at once — and the head-to-head data against semaglutide suggests that engineering paid off. ”

Two receptors. That's the short version. Here's what each one actually does.

GLP-1 receptors (glucagon-like peptide-1) are found throughout the body — in the pancreas, the brain, the stomach, and the heart. When tirzepatide activates GLP-1 receptors in the pancreas, it triggers insulin release in proportion to how much glucose is in your blood. This is the "glucose-dependent" part of its mechanism — it stimulates insulin only when blood sugar is elevated, which is why hypoglycemia (dangerously low blood sugar) is rare compared to older diabetes drugs. GLP-1 receptor activation in the brain suppresses appetite signals and increases the sense of fullness. In the stomach, it slows gastric emptying — food moves through more slowly, which extends satiety after meals.

GIP receptors (glucose-dependent insulinotropic polypeptide) work through a complementary pathway. GIP is actually the first incretin hormone discovered — it was identified before GLP-1 — but it fell out of favor for drug development because people with type 2 diabetes show a blunted GIP response, which led researchers to assume it wasn't useful therapeutically. Tirzepatide's clinical results suggest that assumption was wrong. GIP receptor activation appears to amplify the insulin-secreting effects of GLP-1 signaling, may improve fat cell metabolism directly, and could reduce some of the GI side effects that come with pure GLP-1 agonism.^[2] The exact mechanism for that last point is still being worked out — but patients on tirzepatide do report somewhat better GI tolerability than equivalent doses of semaglutide in some head-to-head comparisons.

The 39-amino acid structure of tirzepatide includes a C20 fatty diacid chain attached via a linker, which is what gives it the ~5-day half-life and allows once-weekly dosing. Without that modification, the peptide would be cleared from the body within minutes.

SURMOUNT-1 (obesity, no T2D): The primary obesity trial enrolled adults with a BMI of 30 or higher (or 27+ with a weight-related comorbidity) but without type 2 diabetes.^[1] At 72 weeks, mean weight loss was approximately 15% at 5 mg, 19.5% at 10 mg, and 22.5% at 15 mg, compared to 2.4% for placebo. Roughly 57% of participants on 15 mg lost at least 20% of their body weight. That figure — more than half of patients losing a fifth of their body weight — had no precedent in pharmaceutical weight management before this trial.

SURPASS-2 (T2D, head-to-head vs. semaglutide): Over 40 weeks in patients with type 2 diabetes, all three tirzepatide doses (5 mg, 10 mg, 15 mg) outperformed semaglutide 1 mg on both HbA1c reduction and weight loss.^[2] The 15 mg dose reduced HbA1c by a mean of 2.46 percentage points — moving many patients from poorly controlled to well-controlled diabetes by that metric alone. Weight loss at 15 mg averaged 12.4 kg (about 27 lbs), versus 6.2 kg for semaglutide.

SURMOUNT-4 (weight maintenance): After an initial 36-week open-label period where all participants received tirzepatide, the trial randomized patients to continue tirzepatide or switch to placebo for 52 more weeks.^[3] Continued tirzepatide produced an additional ~5.5% weight loss; placebo led to regain of roughly two-thirds of the initial weight lost. The trial confirmed what the mechanism predicts: stopping the drug reverses most of the effect.

SURMOUNT-OSA (obstructive sleep apnea): A 2024 trial published in the New England Journal of Medicine tested tirzepatide specifically in adults with moderate-to-severe obstructive sleep apnea and obesity.^[4] Tirzepatide significantly reduced the apnea-hypopnea index (AHI, the standard measure of sleep apnea severity) compared to placebo. This was notable enough that the FDA approved tirzepatide (Zepbound) for obstructive sleep apnea in adults with obesity in June 2024 — making it the first drug approved for that indication.

What We Don't Know Yet

• Long-term cardiovascular outcomes — Semaglutide has the SELECT trial showing a 20% reduction in major cardiovascular events in people with obesity and established CVD. Tirzepatide has the SURPASS-CVOT trial ongoing, but no published outcomes data yet. We can't assume the CV benefit transfers just because the weight loss is greater. [VERIFY: SURPASS-CVOT current status]
• Very long-term safety beyond 3 years — The longest trials run about 72-88 weeks. We don't have 5- or 10-year safety data.
• Thyroid cancer risk in humans — Rodent studies showed thyroid C-cell tumors with GLP-1 receptor agonists. This has not been observed in humans across years of post-marketing surveillance for the GLP-1 class, but tirzepatide carries a black box warning because the human risk hasn't been definitively ruled out.
• Fertility and pregnancy safety — There's no adequate human data on tirzepatide use during pregnancy. Animal studies showed fetal harm at doses relevant to human exposure. Women of childbearing age using oral hormonal contraceptives should be aware that tirzepatide's gastric emptying effects may reduce contraceptive absorption, particularly after the first dose.^[5] The manufacturer recommends using a non-oral backup method for four weeks after each dose escalation.
• Head-to-head obesity trial vs. semaglutide 2.4 mg — The SURPASS-2 comparison used semaglutide 1 mg (the diabetes dose), not the 2.4 mg obesity dose. A direct head-to-head at full obesity doses hasn't been published.

Tirzepatide's side effect profile follows the same general pattern as the GLP-1 class, but the dual mechanism does appear to shift the distribution slightly.

During dose escalation (roughly weeks 1–20):

• Nausea — the most common complaint, typically peaking in the 24–48 hours after each injection and improving within a few days. Worst during the first few escalation steps; most people report it becoming much more manageable by the time they reach their maintenance dose.
• Vomiting and diarrhea — reported less frequently than nausea but can occur, especially if you eat a large or high-fat meal around injection time. Smaller meals, lower fat content on injection day, and staying hydrated help most people manage this.
• Decreased appetite — technically an intended effect, but some patients find it more dramatic than expected early on and struggle to eat enough. Prioritizing protein intake matters during this phase.

At stable maintenance dose:

• Constipation — more common at higher doses and tends to emerge after the initial GI effects settle down. Adequate fiber and hydration are the practical fix for most people; some require a stool softener.
• Injection site reactions — mild redness, itching, or tenderness at the injection site. Rotating sites (abdomen, thigh, upper arm) and allowing the pen to reach room temperature before injecting both reduce this.
• Fatigue — reported by some patients, particularly early in treatment. Usually transient.

Rare but worth knowing:

• Pancreatitis — a class-level concern across all GLP-1 drugs. Abdominal pain that radiates to the back, especially with nausea and vomiting, warrants stopping the medication and contacting your provider immediately.
• Gallbladder issues — rapid weight loss of any cause increases gallstone risk, and tirzepatide is no exception. Acute cholecystitis has been reported in trials.
• Hypoglycemia — uncommon when tirzepatide is used alone because of its glucose-dependent mechanism. Risk increases meaningfully if you're also on insulin or a sulfonylurea.

If you experience severe or persistent abdominal pain, signs of an allergic reaction (difficulty breathing, facial swelling), or vision changes, contact your provider the same day — don't wait for your next scheduled appointment.

FDA Approval Status — as of March 2026

Tirzepatide is FDA-approved under two indications:

• Mounjaro — type 2 diabetes management (approved May 2022)
• Zepbound — chronic weight management in adults with obesity or overweight with a weight-related condition (approved November 2023); also approved for obstructive sleep apnea in adults with obesity (approved June 2024)

Both require a prescription from a licensed healthcare provider. Tirzepatide is not a controlled substance.

Compounded tirzepatide: During the period when branded tirzepatide was on the FDA's drug shortage list, licensed 503B outsourcing facilities and 503A compounding pharmacies were legally permitted to compound tirzepatide. The FDA removed tirzepatide from its shortage list in late 2024, which triggered restrictions on compounding. FDA enforcement against compounders of tirzepatide has been ongoing since then. If you're currently using or considering compounded tirzepatide, verify the current legal status with your prescriber and the compounding pharmacy directly — this regulatory situation has been actively evolving and the rules may have changed since this page was last reviewed.

Insurance coverage: Mounjaro has relatively broad coverage for type 2 diabetes. Zepbound coverage for obesity is patchier — many commercial plans cover it, Medicare Part D plans gained authority to cover obesity drugs under the Inflation Reduction Act, but coverage varies significantly by plan and state. Eli Lilly's savings programs have reduced out-of-pocket costs for commercially insured patients, but cash-pay pricing for branded tirzepatide runs several hundred dollars per month without assistance.

If you're trying to decide between tirzepatide and semaglutide, the honest comparison looks like this:

Tirzepatide vs. Semaglutide: Key Differences

Parameter	Tirzepatide	Semaglutide 2.4 mg
Receptors targeted	GIP + GLP-1	GLP-1 only
Peak trial weight loss	22.5% (72 wk, SURMOUNT-1)	14.9% (68 wk, STEP 1)
FDA approval (obesity)	Yes — Zepbound	Yes — Wegovy
Dosing frequency	Once weekly	Once weekly
Head-to-head vs. semaglutide 1 mg (T2D)	Superior on HbA1c + weight	Comparator arm
CV outcomes data	Pending (SURPASS-CVOT)	Yes — SELECT trial
Approved for sleep apnea	Yes (2024)	No

The weight loss numbers favor tirzepatide clearly, but there's an important caveat: we don't have a head-to-head obesity trial comparing tirzepatide to semaglutide 2.4 mg (the Wegovy dose). The SURPASS-2 comparison used semaglutide 1 mg. Cross-trial comparisons are imperfect because patient populations differ. Semaglutide also has the SELECT cardiovascular outcomes trial showing a 20% reduction in major cardiac events in high-risk patients — tirzepatide doesn't have equivalent published CV data yet.

For a deeper comparison, see our tirzepatide vs. semaglutide breakdown and the retatrutide page if you want to see where the next generation of this drug class is heading.